MedTrace Logo

Experimental Trial of rhIFNα Nasal Drops to Prevent 2019-nCOV in Medical Staff

NCT04320238 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 2944

Last updated 2020-03-31

No results posted yet for this study

Summary

The investigators plan to carry out an experimental study on the preventive effect of recombinant human interferon alpha nasal drops on the infection of 2019 new coronavirus in medical staff.

Conditions

  • 2019 Novel Coronavirus Infection

Interventions

DRUG

recombinant human interferon Alpha-1b

recombinant human interferon Alpha-1b nasal drops, 2-3 drops for each nostril per time, 4 times per day.

DRUG

thymosin alpha 1

thymosin alpha 1 subcutaneous injection 1 time per week.

Sponsors & Collaborators

  • Shanghai Jiao Tong University School of Medicine

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-01-21
Primary Completion
2020-05-31
Completion
2020-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04320238 on ClinicalTrials.gov